Presentation is loading. Please wait.

Presentation is loading. Please wait.

Business Meeting IG Infection & Allergy Monday 18 th June 2012 Agenda 1.Lecture: "Clinical relevance of superantigens in allergic disease. Task force conclusions".

Similar presentations


Presentation on theme: "Business Meeting IG Infection & Allergy Monday 18 th June 2012 Agenda 1.Lecture: "Clinical relevance of superantigens in allergic disease. Task force conclusions"."— Presentation transcript:

1 Business Meeting IG Infection & Allergy Monday 18 th June 2012 Agenda 1.Lecture: "Clinical relevance of superantigens in allergic disease. Task force conclusions". Professor Philippe Gevaert, Chair of the Task Force on Superantigens. 2.IG board and membership 3.I&A sessions at EAACI 2012 4.I&A Allergy School Edinburgh 5.Influenza vaccination in allergy – questionnaire 6.Influenza summit Brussels 7.New I&A task force – suggestions please

2 Board 2011-2013 ChairpersonJürgen Schwarze United Kingdom jurgen.schwarze@ed.ac.uk SecretaryChrysanthi Skevaki Greece cskevaki@allergy.gr MembersCarsten Flohr carsten.flohr@kcl.ac.uk Philippe Gevaert philippe.gevaert@UGent.be JMA AffiliateHeidi Makrinioti heidimakrinioti@gmail.com WebmasterChrysanthi Skevaki cskevaki@allergy.gr

3 Membership (2010-2012)

4 I&A Sessions at EAACI 2012 Oral abstract sessions Sunday, 17 June 2012 10:30 - 12:00 "Role of infections in chronic inflammation" Tuesday, 19 June 2012 15:30 - 17:00 "Interplay between infections and allergy"

5 Saturday, 16 June 2012 14:00 - 15:30 From Innate immunity to allergy Intestinal microbiota and allergic immune response, Charles Mackay, Australia Sunday, 17 June 2012 13:30 - 15:00 Symposium Novel epidemiological insights on asthma and infection Respiratory virus in the inception of childhood asthma, Robert Lemanske, United States Role of rhinovirus C in childhood asthma, Peter Le Souef, Australia Bacterial colonisation as a risk factor for initiation and expression, Hans Bisgaard, Denmark 15:30 - 17:00 Symposium How can anti-infective drugs influence allergic disease? Antivirals, Peter Openshaw, United Kingdom Antibiotics, Thibaut van Zele, Belgium Antiparasitics, Maria Yazdanbakhsh, The Netherlands 15:30 - 17:00 Symposium Microbiota, nutrition and allergic diseases Probiotics and prebiotics for the prevention and treatment, Matthias Kopp, Germany 15:30 - 17:00 JMA Scientific Symposium Bronchiolitis and the infant immune system, Maggina Paraskevi, Greece

6 Monday, 18 June 2012 07:00 - 07:45 Meet the Experts Meet the Expert 15 - Vaccinations in allergic children, Christoph Gruber, Germany 09:00 - 10:30 Plenary Symposium 4 Revisiting the origins of allergy How does the microenvironment shape the allergic response?, Stephen Holgate, United Kingdom 10:45 - 12:15 symposium Understanding urticaria Germs and worms in urticaria, Peter Schmid-Grendelmeier, Switzerland 13:30 - 15:00 Business Meeting Interest Group Infections & Allergy Clinical relevance of superantigens in allergic disease. Task force conclusions, Philippe Gevaert, Belgium 15:30 - 17:00 Symposium Viral mechanisms in airway inflammation Innate immune mechanisms in viral bronchiolitis - from mouse to infant, Riny Janssen, The Netherlands Interferon response in virus-induced asthma, Sebastian Johnston, united Kingdom Viral and bacterial interactions: their role in driving airway inflammation, Chrysanthi Skevaki, Greece 15:30 - 17:00 Symposium EAACI meets Russia The interaction of RSV and epithelial cells in the lung, Musa Khaitov, Russia

7 Tuesday, 19 June 2012 08:30 - 10:00 Meet the Expert 21 Environmental pressure on epigenetic changes, William Cookson, United Kingdom 13:00 - 13:30 Pro & Con 6 Probiotics and prebiotics can reduces the incidence of infantile eczema, Pro: Philippe Eigenmann, Switzerland Con: Matthias Kopp, Germany 15:30 - 17:00 Business Meeting Asthma Section Asthma exacerbation, Sebastian Johnston 15:30 - 17:00 Business Meeting Pediatrics Section Prebiotics and probiotics in allergy prevention and treatment: true or false?, Hania Szajewska, Poland Wednesday, 20 June 2012 08:30 - 10:00 Plenary Symposium 7 Risk factors for allergy Infections at the inception of allergy, Nikos Papadopoulos, Greece 10:30 - 12:00 Symposium Molecular profiling of allergy and inflammation Immunoproteomics: inflammatory response to staphylococcal superantigens, Barbara Broker,

8 Clinical Impact and Mechanisms of Infections in Allergy 15 – 18 September 2011 Edinburgh, UK 8

9 9 Clinical impact and mechanisms of infections in allergy 15 – 18 September 2011 Edinburgh, UK 63 participants & 19 speakers EAACI Members 13 EAACI Juniors 34 Non EAACI14 63 28 Countries UK18 Russia13 Germany8 Greece5 Austria, Belgium, Poland, The Netherlands 3 Switzerland, Thailand, Brazil, Republic of Korea, Slovenia, Romania 2 Ghana, Denmark, Kazakhstan, Canada, Portugal, USA, Uzbekistan, Sweden, Albania, India, Czech Republic, Bosnia, Japan, Turkey 1 ALLERGY SCHOOLS 2011 Local organizer: Jürgen Schwarze 13 CME credits

10 Influenza vaccination in allergy questionnaire 241 respondents 60% allergists, 30% paediatricians The majority of participants (82%) advocate their patients to become vaccinated Half of participants have been involved in influenza immunization programmes IFV immunization of asthmatic/allergic patients is largely performed by GPs and pediatricians

11 Resources for influenza vaccination campaigns are little or not adequate at all Half of participants have been involved in influenza immunization programmes EAACI I&A IG Survey 2012

12 Half of physicians feel that the level of awareness among asthmatics is little or not satisfactory at all EAACI I&A IG Survey 2012

13 What is the vaccination rate of your asthmatic patients? EAACI I&A IG Survey 2012 The majority estimates <40% vaccination coverage of their patients Similarly, low estimates for asthma patients with egg allergy

14 What are the reasons, beliefs, attitudes affecting declination rates among allergic individuals? EAACI I&A IG Survey 2012 Declination of vaccination is strongly affected by a number of misconceptions Education on vaccine efficacy/safety should be one of the priority public health measures taken

15 EAACI I&A IG Survey 2012 Half of respondents report vaccination rates <60% among physicians

16 Additional resources are needed for vaccination campaigns. The level of influenza awareness among patients with asthma should be enhanced. Vaccination rate of asthmatic patients remains low despite recommendations by their physicians. Declination of vaccination among allergic individuals is affected by misconceptions, which may be cleared up with suitable education. Conclusions

17 2 nd ESWI Flu Summit Network of Partner Organizations: European Public Health Alliance, International Diabetes Federation-EU, WHO-EU, ESPID, EAP, EAACI, WONCA-EU, ELF, ERS, EMA, EUGMS, EUREGHA, National Influenza Vaccine Summit, PGEU Showcase successful projects that raised patients’ awareness ~100 representatives of health care providers, senior citizens, at-risk patients and public health authorities: platform to expand efforts, exchange practices and initiate concrete actions, influenza challenges ahead WHO Europe (respir path progr), EC Directorate-General for Health and Consumers, ESWI Chair & Vice-Chair, EMA, American Medical Association, ESPID, Pharmacy Union, EUGMS, Turkish Ministry of Health

18 Reported prevalence of influenza in AAE among children & adults Influenza attributable health care utilization Vaccine Effectiveness (CS intake) Vaccine Efficacy Vaccine Safety Selection of vaccine: TIV vs LAIV Compliance of asthmatics to current vaccine recommendations Task Force: “Influenza in asthma” 18


Download ppt "Business Meeting IG Infection & Allergy Monday 18 th June 2012 Agenda 1.Lecture: "Clinical relevance of superantigens in allergic disease. Task force conclusions"."

Similar presentations


Ads by Google